Law360 (February 23, 2010, 4:05 PM EST) -- A federal judge has thrown out suits by the Federal Trade Commission and private plaintiffs challenging patent settlements in which Solvay Pharmaceuticals Inc. paid generic-drug makers not to compete with its testosterone supplement AndroGel, joining other federal courts in upholding drug companies' right to make so-called reverse payment deals.
Judge Thomas W. Thrash of the U.S. District Court for the Northern District of Georgia ruled Tuesday the settlements were legal because they didn't extend Solvay's monopoly on AndroGel past the expiration of its patent on the drug, citing a similar finding by the U.S. Court of Appeals for the Eleventh Circuit...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!